Related Experiment Video
Updated: May 20, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
Cancer cachexia: mediators, signaling, and metabolic pathways
Kenneth C H Fearon1, David J Glass, Denis C Guttridge
1Clinical Surgery, School of Clinical Sciences and Community Health, University of Edinburgh, Royal Infirmary, Edinburgh EH16 4SA, UK. k.fearon@ed.ac.uk
Cancer cachexia causes significant weight loss and impacts patient quality of life. Understanding conserved molecular mechanisms of muscle atrophy offers a promising therapeutic target for this unmet medical need.
Area of Science:
- Oncology
- Metabolism
- Molecular Biology
Background:
- Cancer cachexia is a complex syndrome causing significant weight loss, primarily from muscle and fat tissue depletion.
- It severely impacts cancer treatment tolerance, patient quality of life, and survival, representing a critical unmet medical need.
- Therapeutic development is hindered by the heterogeneity of signaling pathways and metabolic disruptions in cachexia.
Purpose of the Study:
- To explore conserved molecular mechanisms underlying skeletal muscle atrophy in cancer cachexia.
- To identify potential downstream therapeutic targets that bypass upstream mediator variability.
- To provide a foundation for developing novel targeted therapies for cancer cachexia.
Main Methods:
- Review of recent advancements in understanding molecular mechanisms of skeletal muscle atrophy and hypertrophy.
- Analysis of conserved pathways involved in cancer cachexia.
- Identification of potential therapeutic targets based on molecular mechanisms.
Main Results:
- Progress has been made in understanding conserved molecular mechanisms governing skeletal muscle atrophy.
- These conserved mechanisms offer a potential platform to overcome the heterogeneity of upstream mediators in cachexia.
- Focusing on downstream molecular pathways may circumvent upstream variations.
Conclusions:
- Conserved molecular mechanisms of skeletal muscle atrophy represent a promising therapeutic avenue for cancer cachexia.
- Targeting these downstream pathways could lead to more effective treatments for this debilitating condition.
- Further research into these mechanisms may translate into new therapies to improve patient outcomes.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway
Non-Canonical Wnt Signaling Pathways
Autocrine Signaling
Autocrine Signaling in Macrophages
Under normal physiological conditions, autocrine signaling is essential for maintaining homeostasis. This process is well characterized in...

